Cargando…

Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data

Reported median overall survival (mOS) in metastatic colorectal cancer (mCRC) patients participating in systemic therapy trials has increased to over 30 months. It is uncertain whether trial results translate to real‐life populations. Moreover, patients prefer presentation of multiple survival scena...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamers, Patricia A. H., Elferink, Marloes A. G., Stellato, Rebecca K., Punt, Cornelis J. A., May, Anne M., Koopman, Miriam, Vink, Geraldine R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Cancer Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754475/ https://www.ncbi.nlm.nih.gov/pubmed/32638384 http://dx.doi.org/10.1002/ijc.33200

Ejemplares similares

Time‐varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: A population‐based study and meta‐analysis
por: van der Kruijssen, Dave E. W., et al.
Publicado: (2022)

Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real‐world data
por: Jongeneel, Gabrielle, et al.
Publicado: (2019)

Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: A prospective cohort study
por: Jongeneel, Gabrielle, et al.
Publicado: (2021)

Translation of IDEA trial results into clinical practice: Analysis of the implementation of a new guideline for colon cancer
por: van Rooijen, Karlijn L., et al.
Publicado: (2022)

Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort
por: Zwart, Koen, et al.
Publicado: (2023)

Sex differences in metastatic surgery following diagnosis of synchronous metastatic colorectal cancer
por: Ljunggren, Malin, et al.
Publicado: (2022)

The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care
por: Derksen, Jeroen W. G., et al.
Publicado: (2021)

Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients
por: Kurk, Sophie A, et al.
Publicado: (2019)

Predicting early extrahepatic recurrence after local treatment of colorectal liver metastases
por: Wensink, G E, et al.
Publicado: (2023)

Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world database
por: Mailliez, Audrey, et al.
Publicado: (2022)

Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial
por: Kurk, Sophie A., et al.
Publicado: (2019)

The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival
por: Brouwer, Nelleke P. M., et al.
Publicado: (2019)

External Validation of the Colon Life Nomogram for Predicting 12-Week Mortality in Dutch Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil in Daily Practice
por: Hamers, Patricia A. H., et al.
Publicado: (2022)

Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature
por: Venderbosch, Sabine, et al.
Publicado: (2011)

Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients
por: Kurk, Sophie, et al.
Publicado: (2019)

To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low‐resource settings
por: Campos, Nicole G., et al.
Publicado: (2017)

Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer
por: Nanou, Afroditi, et al.
Publicado: (2020)

Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer
por: Derksen, Jeroen W G, et al.
Publicado: (2019)

An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients
por: Brouwer, Nelleke P.M., et al.
Publicado: (2018)

Umbilical metastases: Real‐world data shows abysmal outcome
por: Hugen, Niek, et al.
Publicado: (2021)

Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients
por: Kurk, Sophie A., et al.
Publicado: (2018)

Diabetes mellitus in relation to colorectal tumor molecular subtypes: A pooled analysis of more than 9000 cases
por: Harlid, Sophia, et al.
Publicado: (2022)

Energy balance‐related factors in childhood and adolescence and risk of colorectal cancer expressing different levels of proteins involved in the Warburg‐effect
por: Jenniskens, Josien C. A., et al.
Publicado: (2022)

Plasma metabolites associated with colorectal cancer stage: Findings from an international consortium
por: Geijsen, Anne J.M.R., et al.
Publicado: (2019)

Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018
por: Board, Ruth, et al.
Publicado: (2020)

Incidence and mortality trends of gastric and colorectal cancers in Croatia, 1988-2008
por: Kirac, Iva, et al.
Publicado: (2012)

Plasma metabolites associated with colorectal cancer: A discovery‐replication strategy
por: Geijsen, Anne J.M.R., et al.
Publicado: (2019)

Estimating the Effect of Targeted Screening Strategies: An Application to Colonoscopy and Colorectal Cancer
por: Thomas, Duncan C.
Publicado: (2017)

Rotating night shift work and colorectal cancer risk in the nurses’ health studies
por: Papantoniou, Kyriaki, et al.
Publicado: (2018)

MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer
por: Simmer, Femke, et al.
Publicado: (2015)

External Validation of Two Established Clinical Risk Scores Predicting Outcome after Local Treatment of Colorectal Liver Metastases in a Nationwide Cohort
por: Bolhuis, Karen, et al.
Publicado: (2022)

Heterogeneity of colorectal cancer risk by tumour characteristics: Large prospective study of UK women
por: Burón Pust, Andrea, et al.
Publicado: (2017)

Shared environment and colorectal cancer: A Nordic pedigree registry‐based cohort study
por: Elmahdi, Rahma, et al.
Publicado: (2022)

One‐carbon metabolite ratios as functional B‐vitamin markers and in relation to colorectal cancer risk
por: Gylling, Björn, et al.
Publicado: (2018)

Cell-Free Circulating (Tumor) DNA before Surgery as a Prognostic Factor in Non-Metastatic Colorectal Cancer: A Systematic Review
por: Schraa, Suzanna J., et al.
Publicado: (2022)

Radiation risk of incident colorectal cancer by anatomical site among atomic bomb survivors: 1958–2009
por: Sugiyama, Hiromi, et al.
Publicado: (2019)

Characteristics of nonparticipants in a randomised colorectal cancer screening trial comparing sigmoidoscopy and faecal immunochemical testing
por: Botteri, Edoardo, et al.
Publicado: (2022)

Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
por: Patel, Anuj K., et al.
Publicado: (2019)

Longitudinal associations of plasma metabolites with persistent fatigue among colorectal cancer survivors up to 2 years after treatment
por: van Roekel, Eline H., et al.
Publicado: (2022)

Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma
por: Hegewisch‐Becker, Susanna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_41fm62nkoiklk51cfc5lgmc2f9